Singapore, Oct. 29 -- International Union Against Tuberculosis and Lung Disease (The Union) headquartered in France, announces the Phase IIb Trial results of its Tuberculosis Vaccine Candidate GSK/IAVI M72. The Union is convenor of the 50th Union World Conference on Lung Health being held in Hyderabad, India, this week.

We are one more cautious, but exciting, step closer to a vaccine for tuberculosis (TB)," said Dr Paula I Fujiwara, Scientific Director of the International Union Against Tuberculosis and Lung Disease (The Union). "A vaccine is the ultimate prevention tool and the announcement today is welcome news, but as researchers discuss how to move the trial into its final phase, we simultaneously need to be doing all we can to preve...